Loading
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Previous close
$0.6251
−$0.1241 · -16.56%
Regular session · ET · Market data may be delayed.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Day range
Current $0.6251
52-week range
Current $0.6251
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
46
Fair Value
Sentiment
55
Mixed
Risk
73
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Day range
Current $0.6251
52-week range
Current $0.6251
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 5.05M USD | 3.38M USD | 90K USD | 111K USD | 283K USD |
| Selling, general, and administrative | 31.7M USD | 12.04M USD | 5.17M USD | 3.05M USD | 2.89M USD |
| Operating expenses | 36.76M USD | 15.42M USD | 5.26M USD | 3.16M USD | 3.17M USD |
| Interest income | 28K USD | 13K USD | 15K USD | 1.98M USD | — |
| Interest expense | 319K USD | 1.51M USD | 211K USD | — | — |
| Depreciation and amortization | 2.43M USD | 457K USD | — | — | — |
| Operating income | −36.76M USD | −15.42M USD | −5.26M USD | −3.16M USD | −3.17M USD |
| Net income | −39.22M USD | −17.8M USD | −535K USD | −4.89M USD | −3.66M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 20, 2026 | 1:10 | — | — |
Stock split | Mar 27, 2026 | 1:25 | — | — |
Stock split | Oct 13, 2025 | 1:8 | — | — |
Stock split | May 20, 2025 | 1:15 | — | — |
Stock split | Jan 27, 2025 | 1:100 | — | — |
Effective Jul 20, 2026
1:10
Effective Mar 27, 2026
1:25
Effective Oct 13, 2025
1:8
Effective May 20, 2025
1:15
Effective Jan 27, 2025
1:100
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
